Patients with end-stage kidney disease who have spent years on transplant waitlists now face a new clinical reality: two separate companies have cleared FDA regulatory gates to test gene-edited pig kidneys in living recipients, and the first transplant in a formal clinical trial has already taken place at NYU Langone. United Therapeutics is running the EXPAND trial, while eGenesis has secured its own investigational new drug clearance for a competing product called EGEN-2784. The two programs differ sharply in how many genetic changes they make to donor pig organs, and those differences could shape whether xenotransplantation becomes a reliable solution for the roughly 100,000 Americans waiting for a kidney.
Two rival pig kidney trials and why their design gap matters
United Therapeutics is sponsoring the EXPAND study, an interventional trial evaluating what the company calls the 10 GE Xenokidney in patients with end-stage renal disease. The “10 GE” label refers to 10 genetic edits applied to the donor pig line. That number stands in stark contrast to a separate case reported in the New England Journal of Medicine, which documented a porcine kidney transplant involving 69 genetic edits, including antigen deletions, porcine endogenous retrovirus (PERV) inactivation, and the insertion of human transgenes designed to reduce immune rejection.
The gap between 10 edits and 69 edits is not just a number. It reflects fundamentally different engineering philosophies. A smaller edit count can simplify manufacturing, quality control, and regulatory review but may leave more pig-specific immune triggers intact. A larger edit count, particularly one that inserts multiple human transgenes, aims to make the organ look more like native human tissue to the recipient’s immune system and to dampen clotting or inflammatory cascades that can destroy a graft within days. Which approach produces longer graft survival in actual patients is the central unanswered question of the next 12 to 18 months.
eGenesis, the second company in the race, received FDA clearance of an investigational new drug application for its EGEN-2784 kidney, supporting a Phase 1/2/3 study with a primary evaluation window at 24 weeks. The trial targets patients aged 50 and older who are dialysis-dependent and already on the kidney transplant waitlist. That eligibility design signals that regulators and the company alike expect to measure whether a pig kidney can sustain a patient through six months of real-world function, not just survive a few weeks of observation under intensive monitoring.
On paper, EGEN-2784 appears closer to the high-edit philosophy. The company has previously emphasized extensive PERV inactivation and multiple human gene insertions in its porcine donor lines, aiming to reduce the risk of viral transmission and blunt both innate and adaptive immune responses. United Therapeutics, by contrast, is testing whether a more conservative set of modifications can still deliver clinically meaningful graft survival when paired with modern immunosuppression. For patients and clinicians, the trade-off is not academic: more edits could mean a more “humanized” organ but also a more complex and potentially fragile manufacturing process.
What the first transplant and peer-reviewed data actually show
The first transplant under United Therapeutics’ formal trial protocol took place at NYU Langone, with the company confirming the procedure and independent reporting corroborating it. The initial cohort is small, consistent with a safety-focused early phase that typically enrolls only a handful of patients before any dose or protocol adjustments. As of this writing, no public data on immunosuppression regimens, biopsy findings, or short-term graft function from EXPAND have been released, leaving outside observers to infer likely approaches from preclinical work.
The peer-reviewed New England Journal of Medicine case provides the closest thing to detailed clinical evidence available so far. That report described a living-human porcine kidney transplant using the 69-edit construct, detailing the patient’s preexisting renal failure, the surgical procedure, and the observed outcomes over the clinical course. The 69 edits broke down into three broad categories: removal of pig antigens that trigger hyperacute rejection, inactivation of PERV sequences embedded in the pig genome, and insertion of human transgenes meant to modulate complement activation, coagulation, and cellular immune responses.
Regulators have been moving toward this moment for years. According to a Nature Biotechnology report, the FDA has now granted multiple IND approvals for xenotransplant clinical trials, effectively formalizing standards for donor animal screening, viral safety, and long-term patient follow-up. That framework gives hospitals and sponsors a clearer path to scale beyond single compassionate-use cases, but it also raises the bar for data collection, including mandatory registries and post-trial surveillance.
Still, the field is operating with thin human evidence. The NEJM case, while rich in mechanistic detail, represents a single patient and cannot answer population-level questions about six-month or one-year survival. Nor can it fully disentangle the contribution of each genetic change from the effects of aggressive immunosuppression and meticulous supportive care. For now, every new transplant is as much an experiment in clinical operations as it is a test of genetic engineering strategy.
Gaps in the evidence and what patients should watch for
Several important details remain absent from the public record. The ClinicalTrials.gov listing for EXPAND does not specify a recruitment start date, the number of clinical sites, or an enrollment target beyond basic eligibility criteria. Without those details, patients and referring nephrologists cannot yet gauge how quickly the trial will generate meaningful safety data or how broadly access will extend beyond NYU Langone and a small number of early adopters.
The eGenesis program faces a similar transparency gap. Public announcements describe a Phase 1/2/3 design with a 24-week primary endpoint and reference ongoing expanded-access experience, but do not yet provide a site list, detailed inclusion and exclusion criteria, or clear guidance on how many patients will be enrolled in each phase. For individuals on dialysis, that opacity makes it difficult to know whether participation is a realistic near-term option or a distant possibility.
Beyond logistics, three scientific unknowns loom large for patients considering xenotransplantation. First is durability: can a gene-edited pig kidney support stable filtration and fluid balance for at least six to 12 months without catastrophic rejection or thrombotic microangiopathy? Second is safety: even with PERV inactivation and intensive screening, regulators will be watching closely for any signs of zoonotic infection, unexpected malignancies, or off-target drug toxicities in immunosuppressed recipients. Third is quality of life: if a pig kidney functions but requires more intensive clinic visits, biopsies, or drug monitoring than a human allograft, some patients may prefer to remain on the waitlist for a human organ.
Patients and clinicians weighing enrollment should watch for several early signals as data emerge. Time to dialysis independence after surgery, stability of creatinine and urine output over the first three months, and the incidence of acute rejection episodes will offer the first hints of whether these organs behave more like marginal human kidneys or something entirely new. The nature and intensity of the required immunosuppression will also matter: a regimen that relies on exceptionally high drug doses may keep the graft alive but at the cost of higher infection and cancer risks.
Ethical and equity questions will follow close behind any technical success. If pig kidneys prove viable, payers and policymakers will need to decide how to reimburse procedures that may initially be offered only at a handful of academic centers. Patients from rural or underserved communities could face new disparities in access, even as the overall organ supply increases. Informed consent documents will have to grapple not only with standard surgical risks but also with unknown long-term consequences of living with a genetically engineered animal organ.
For now, the most realistic expectation is that early xenotransplant recipients will be pioneers rather than typical patients. Their experiences-positive or negative-will shape how quickly regulators expand trial enrollment, how aggressively companies invest in manufacturing scale, and how transplant programs counsel the next wave of candidates. Until more data are in hand, nephrologists are likely to continue steering most patients toward conventional options: optimized dialysis, human kidney transplantation when available, and participation in less experimental trials.
The arrival of two competing gene-edited pig kidney programs marks a turning point, but not yet a solution. Over the next few years, the field will have to prove that these organs can deliver not just survival, but sustainable, safe, and broadly accessible kidney replacement. Patients on today’s waitlists may not see definitive answers immediately, but the trajectory of xenotransplantation has shifted from speculative to testable-and the outcomes of EXPAND, EGEN-2784, and similar trials will determine whether it becomes a standard part of renal care or remains a niche experiment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
